神経調節装置市場：セグメント別規模、シェア、法規制、償還、手技、2036年までの予測

神経調節装置は、神経系の活動を調節することで、様々な神経疾患や精神疾患を治療するために使用される医療機器です。神経調節装置は、神経系の標的領域に電気的または磁気的刺激を与えることで機能します。神経調節装置は、薬物療法や手術といった従来の神経疾患や精神疾患の治療に代わる選択肢を提供します。脳深部刺激装置（DBS）、胃電気刺激装置（GES）、リード、仙骨神経刺激装置（SNS）、脊髄刺激装置（SCS）、末梢神経刺激装置（PNS）、迷走神経刺激装置（VNS）などがこのカテゴリーに含まれます。

高齢化社会に影響を及ぼす神経疾患の有病率が高いため、この巨大な高齢者人口基盤が神経調節市場の大きな促進要因となっています。

当レポートは、世界の神経調節装置市場について詳細に考察し、市場における競合情勢、SWOT分析、2036年までの市場予測、地域、国別の動向などを提供しています。

目次

現在上市されている神経調節装置と競合情勢

• 主要な業界動向の洞察
• 神経調節装置のセグメント別総市場収益と2015年～2036年の市場展望
• 台数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

• 神経調節装置市場のSWOT分析
• 神経調節装置市場に関する競合力学の洞察と動向
• 国別の医療制度の概要
• 国別の償還政策
• 国別の医療技術に関する規制の状況

Neuromodulation Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2036 is built to visualize quantitative and qualitative market trends within Neurology Devices therapeutic area.

Neuromodulation devices are medical devices that are used to treat various neurological and psychiatric disorders by modulating the activity of the nervous system. Neuromodulation Devices work by delivering electrical or magnetic stimulation to targeted areas of the nervous system. Neuromodulation devices offer an alternative to traditional treatments for neurological and psychiatric disorders, such as medications and surgery. Deep brain stimulators (DBS), gastric electric stimulators (GES), leads, sacral nerve stimulators (SNS), spinal cord stimulators (SCS), peripheral nerve stimulators (PNS) and vagus nerve stimulators (VNS) are the segments covered under this category.

Due to the large prevalence of neurological conditions impacting the aging population, this huge geriatric population base is a large driver of the neuromodulation market.

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Neuromodulation Devices and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total Neuromodulation Devices market revenue by segment and market outlooks from 2015-2036.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Neuromodulation Devices market.
• Competitive dynamics insights and trends provided for Neuromodulation Devices market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered - Medtronic Plc, Abbott Laboratories, Boston Scientific Corp, LivaNova Plc, Nevro Corp, AirLife, Beijing Pins Medical Co Ltd, Curonix LLC, Bioness Inc, Avanos Medical Inc, B. Braun Melsungen AG, Axonics Inc, NeuroPace Inc, Xavant Technology (Pty) Ltd, Enterra Medical Inc and Others

Countries covered - United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Neuromodulation Devices marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving Neuromodulation Devices market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Neuromodulation Devices market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Neuromodulation Devices market from 2015-2036.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.